Literature DB >> 28290492

Haematological cancer: Treg predict responsiveness to blinatumomab.

Peter Sidaway.   

Abstract

Entities:  

Year:  2017        PMID： 28290492     DOI： 10.1038/nrclinonc.2017.36

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.

Authors:  J Duell; M Dittrich; T Bedke; T Mueller; F Eisele; A Rosenwald; L Rasche; E Hartmann; T Dandekar; H Einsele; M S Topp
Journal:  Leukemia       Date:  2017-01-25       Impact factor: 11.528
  1 in total
  2 in total

Review 1.  Syk inhibitors in clinical development for hematological malignancies.

Authors:  Delong Liu; Aleksandra Mamorska-Dyga
Journal:  J Hematol Oncol       Date:  2017-07-28       Impact factor: 17.388

Review 2.  T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.

Authors:  Patrick A Baeuerle; Holger Wesche
Journal:  Curr Opin Oncol       Date:  2022-07-28       Impact factor: 3.915
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.